Time of administration of acute or chronic doses of imipramine affects its antidepressant action in rats by 河合, 洋 et al.
Kawai, H, et al. 2018 Time of Administration of Acute or Chronic Doses of 
Imipramine Affects its Antidepressant Action in Rats. Journal of Circadian 
Rhythms, 16(1): 5, pp. 1–9. DOI: https://doi.org/10.5334/jcr.156
&,5&$',$15+<7+06-2851$/2)
RESEARCH ARTICLE
Time of Administration of Acute or Chronic Doses of 
Imipramine Affects its Antidepressant Action in Rats
Hiroshi Kawai*, Natsumi Kodaira†, Chika Tanaka†, Takuya Ishibashi†, Naomi Kudo*, Yoichi 
Kawashima* and Atsushi Mitsumoto†
The pathogenesis and therapeutics of depression are linked to the operation of the circadian system. Here, 
we studied the chronopharmacological action of a tricyclic antidepressant, imipramine. Male adult Wistar–
Hannover rats were administered imipramine acutely or chronically in the morning or in the evening. The 
antidepressant action of imipramine was analyzed using the forced swim test (FST). A single dose of 
imipramine (30 mg/kg) in the morning, but not in the evening, reduced immobility and increased climbing 
in the FST. The plasma concentrations of imipramine and its metabolite, desipramine, were slightly higher 
in the morning than in the evening, which might explain the dosing time-dependent action of imipramine. 
Next, we analyzed the effect of chronic imipramine treatment. Rats received imipramine in the morning or 
in the evening for 2 weeks. The morning treatment resulted in larger effects in the FST than the evening 
treatment, and was effective at a dose that was ineffective when administered acutely. The levels of 
brain α-adrenergic receptors tended to decrease after chronic imipramine treatment. Imipramine might 
interact with noradrenergic neurons, and this interaction might chronically alter receptor expression. 
This alteration seemed greater in the morning than in the evening, which might explain the dosing time-
dependent action of imipramine.
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Introduction
The pharmacological action of many substances is depen-
dent on the circadian system, and a drug’s dosing time can 
affect both its therapeutic and toxic effects [1–5]. Some 
drugs work better in the daytime, while other drugs work 
better at night. The best timing for a treatment depends on 
the chronopharmacological profile of the drug. Therefore, 
precise knowledge of the chronopharmacological profile 
of a drug is essential to provide effective  medication.
Depression is strongly associated with the circadian sys-
tem. Patients with depression often show a disturbance 
of the circadian rhythm of various physiological func-
tions (e.g., a sleep disturbance). Depression and circadian 
 disturbance may be physiologically linked and deteriorate 
synergistically [6–8]. However, the circadian system has 
been linked not only to the pathogenesis of depression 
but also to its therapeutics [9–13]. Wehr et al. reported 
that the circadian phase was advanced and desynchronized 
with the sleep-wake cycle in patients with  depression, and 
that phase advance of the sleep-wake cycle exerted an 
antidepressant effect [10]. Phase entrainment by bright 
light in the morning is also effective to improve depressive 
symptoms [11–12]. Chronotherapy of depression by the 
combination of sleep deprivation, sleep phase advance, 
and bright light treatment induces rapid  amelioration in 
patients with depression [13]. Some antidepressants can 
interact with and modify the biological clock [14–19]. 
In addition, some antidepressants show dosing time-
dependent action in animal models [20, 21] and in clinical 
settings [22, 23]. However, the therapeutic significance of 
these actions remains to be clarified. Further research on 
the relationship between the  circadian system and depres-
sion could lead to the development of an effective therapy 
for depression.
The forced swim test (FST) is one of the most common 
behavioral tests in rodents. Since the FST has high pre-
dictive validity, reliability, and robustness, it is useful for 
screening and analysis of antidepressant activity [24]. 
However, there is an inconsistency between the effects of 
antidepressants in the FST and those in clinical settings. 
A single dose or 2–3 injections of the antidepressant 
within 24 hours induce reduction of immobility indica-
tive of antidepressant activity in the FST [25–27], whereas 
most antidepressants are ineffective when administered 
acutely or subacutely in clinical settings, usually taking 
several weeks to show therapeutic effects in patients [24]. 
Chronic antidepressant treatment alters brain function by 
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regulating receptor expression levels, which might con-
tribute to alleviating the depressive symptoms [28–30]. 
Those changes are not detectable in acute treatment. 
In order to analyze the biochemical alterations related 
to antidepressant activity, an animal model of chronic 
 treatment would be necessary.
Several animal and clinical studies have reported 
the chronopharmacological action of antidepressants. 
Amitriptyline, fluvoxamine, and milnacipran show dosing 
time-dependent antidepressant activity in rodents [20, 
21]. However, these studies have used an acute treatment 
model with the FST. Several clinical studies  analyzed the 
chronopharmacology of chronic antidepressant treat-
ment [22, 31, 32]. However, no such analysis has been 
performed in animal models. In the present study, we 
aimed to develop a chronic animal model to analyze the 
 chronopharmacological action of the antidepressant imip-
ramine and to reveal the biochemical alterations that 
contribute to the chronopharmacological action of this 
antidepressant in this model. The present study analyzed 
the dosing time-dependent action of imipramine in an 
acute and chronic treatment model using the FST. We also 
analyzed the dosing time-dependent imipramine metab-
olism in the acute model and the dosing time-dependent 
effects of the chronic imipramine treatment on the brain 
levels of the α1 adrenergic receptor (α1AR) and α2 adren-
ergic receptor (α2AR). We hypothesized that the circadian 
fluctuation of imipramine metabolism may induce dosing 
time-dependent changes in the efficiency of the interaction 
between imipramine and the adrenergic system, a target sys-
tem of imipramine. Repeated interaction caused by chronic 
imipramine treatment may induce a dosing time-depend-
ent alteration of  adrenergic receptors protein expression, 
which might contribute to the  chronopharmacological 
antidepressant action of imipramine.
Methods
Chemicals
Imipramine and other chemicals were obtained from 
Wako Pure Chemical Industries (Osaka, Japan), unless 
 otherwise described. Pentobarbital was obtained from 
Kyoritsu Seiyaku (Tokyo, Japan). Protease inhibitor cock-
tail and anti-β-actin antibody (A5441) were obtained from 
Sigma-Aldrich (St. Louis, MO, USA). Anti-α2-adrenergic 
receptor antibody (sc-28983) was obtained from Santa 
Cruz Biotechnology (Dallas, TX, USA). Anti-α1-adrenergic 
receptor antibody (ab137123), anti-rabbit immunoglobu-
lin G (IgG) horseradish peroxidase-conjugated second-
ary antibody (ab97051), and anti-mouse IgG horseradish 
 peroxidase-conjugated secondary antibody (ab79023) 
were obtained from Abcam (Cambridge, MA, USA).
Animals
Male adult Wistar–Hannover rats (weighing 200–250 g) were 
obtained from CLEA Japan (Tokyo), and were  maintained 
in an air-conditioned room at 24 ± 2°C with a 12/12-hour 
light/dark cycle (lights on at 7:00 a.m.). The rats had free 
access to food and water. The time of the day is expressed 
as the zeitgeber time (ZT), defined as follows: the light 
onset time (7:00 a.m. clock time) is ZT0; the dark onset 
time (7:00 p.m. clock time) is ZT12; and ZT24 is the ZT0 
of the next day. Animal maintenance and  treatments 
were in  accordance with the general recommendations of 
 animal protection legislation in Japan. All procedures were 
approved by the Institutional Animal Care and Use Com-
mittee of Josai International University (approval numbers: 
32 and 57).
Schedule for the analysis of the effects of acute 
imipramine treatment
One day before measurement, rats were exposed to the 
FST apparatus as described below. Twenty-three hours 
after the first exposure, rats were intraperitoneally 
 administered 10, 20, 30, or 50 mg/kg of imipramine (as a 
hydrochloride salt) at 8:00 a.m. (ZT1) or 8:00 p.m. (ZT13). 
Control rats were administered saline. One hour after 
administration, the FST was carried out.
Schedule for the analysis of the effects of chronic 
imipramine treatment
Rats were exposed to the FST apparatus as described below, 
and the drug treatment was started the next day. The rats 
were intraperitoneally administered saline or imipramine 
for 2 weeks. To equalize the number and the timing of the 
intraperitoneal injections among the groups, all rats were 
injected twice a day as shown in Table 1. Control rats were 
administered saline at ZT1 and ZT13; the morning group 
was administered imipramine at ZT1 and saline at ZT13; 
and the evening group was administered saline at ZT1 and 
imipramine at ZT13. Two days after the last administra-
tion, the rats were administered imipramine at a low dose 
(10 mg/kg) during the early light period (ZT1–3), and 1 
hour after the administration, the FST was carried out. 
The rats were returned to their home cage after the FST, 
and they were sacrificed for biochemical analysis on the 
next day.
Forced swim test (FST)
We used a modified FST according to the method of 
Detke et al. [26]. On the day before the first treatment 
of imipramine or saline, each rat was individually placed 
in a tank made of an opaque plastic cylinder (24 cm in 
diameter, 50 cm in height) filled with room-temperature 
Table 1: Daily administration schedule for the analysis of chronic imipramine treatment.
Group Administration time
ZT1 ZT13
Control Saline Saline
Morning (imipramine at ZT1) Imipramine Saline
Evening (imipramine at ZT13) Saline Imipramine
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water (24 ± 2°C) to a depth of 30 cm. The rat was left in 
the tank for 10 minutes, then removed from the cylinder, 
allowed to dry in a clean cage, and returned to its home 
cage. On the day of measurement, the rat was again placed 
in the tank of room-temperature water, and its behaviors 
were analyzed for 5 minutes: at regular 5-second inter-
vals, trained observers recorded which of the following 
three behaviors was predominant: immobility, swimming, 
or climbing. The total counts for each behavior over the 
5-minute test session were analyzed as the FST score. All 
tests were observed and scored by two or more trained 
observers to prevent scoring errors.
Analysis of plasma imipramine concentration
Rats were administered intraperitoneally with 30 mg/kg 
of imipramine at ZT1 or ZT13. One hour after administra-
tion, the rats were anesthetized with pentobarbital, and 
blood samples were removed from the postcaval vein with 
a heparinized needle attached to a heparinized syringe. 
The blood samples were centrifuged at 1,200 × g for 10 
minutes to obtain plasma, which were immediately frozen 
in liquid nitrogen and kept at –80°C until use.
Diazepam at 10 nmol was added to 1 mL of plasma as 
an internal standard. The sample was alkalinized with 
0.1 mL of 5 M NaOH and extracted twice with 1 mL of 
n-hexane/methanol (4/1). The organic layer was extracted 
twice with 0.1 mL of 0.05% phosphoric acid. The extract 
was filtered through a 0.45-μm filter. A portion of 
the filtrate was subjected to high-performance liquid 
 chromatography (HPLC) analysis.
Imipramine and desipramine were analyzed with 
HPLC-UV. An LC-10AD/SPD-10A system (Shimadzu, Kyoto, 
Japan) was used. Separation was performed on Gemini 
ODS (2.1 mm in inner diameter × 150 mm, Phenomenex, 
Torrance, CA, USA) with a precolumn (SecurityGuard, 
Phenomenex) at 40°C. The eluents were 80% 50 mM 
sodium phosphate buffer (pH 3.8), 20% acetonitrile. The 
flow rate was maintained at 0.2 mL/minute. Compounds 
were detected at 254 nm.
Analysis of protein in the brain by western blotting
Rats were anesthetized with pentobarbital and sacrificed 
by decapitation. The brain was rapidly dissected out and 
divided into sections. The prefrontal cortex (PFC) and 
 hippocampus were immediately frozen in liquid nitrogen 
and kept at –80°C until use.
The brain tissues were homogenized in 5 volumes of 
lysis buffer (50 mM Tris HCl buffer [pH 7.4], 150 mM NaCl, 
1% Triton X-100, 0.5% sodium deoxycholate, 1% sodium 
dodecyl sulfate [SDS], 1 mM sodium orthovanadate, 1 
mM NaF, 1 mM phenylmethylsulfonyl fluoride [PMSF], 
2 μL/mL of protease inhibitor cocktail), and centrifuged 
at 20,000 × g for 20 minutes at 4°C. The protein contents 
of the supernatant were determined using the bicin-
choninic acid (BCA) assay kit (Thermo Fisher Scientific, 
Waltham, MA, USA). An aliquot of the supernatant was 
used to prepare the SDS sample (1 μg protein/μL in SDS 
loading buffer). The SDS samples were incubated at 95°C 
for 2 minutes, and loaded at 10 μg protein onto 10% SDS-
polyacrylamide gels. Proteins were separated at 60 V and 
then blotted to PVDF membranes in Tris-glycine transfer 
buffer at 100 V for 2 hours. The membrane was  incubated 
with 5% skim milk in phosphate-buffered  saline 
 containing 0.1% Tween-20 (PBS-T) for 1 hour at room tem-
perature, primary antibody overnight at 4°C, and horse-
radish peroxidase-conjugated secondary  antibody for 1 
hour at room temperature. The membrane was washed 
with PBS-T 3 times for 5 minutes after the incubation with 
the primary and secondary antibody. The membrane was 
developed with the ECL prime western blotting detection 
reagent (Amersham, Piscataway, NJ, USA), and analyzed 
using an imaging analyzer LAS-3000 (Fujifilm, Tokyo, 
Japan). Blots with anti-β-actin antibody were used as load-
ing control.
Statistical analysis
Data are expressed as the means ± standard error of the 
mean (SEM). Dose-dependent changes against the  control 
group were analyzed using the Williams test (Figure 1). 
Differences between two groups were analyzed with 
 Student’s t-test (Figure 2). Effects of two factors were 
analyzed using 2-way analysis of variance (ANOVA) 
(Figure 3). Multiple pairwise comparisons among three 
or more groups were analyzed with Tukey’s test (Figures 4 
and 5). The significance level was set at p < 0.05. The JMP 
procedure (SAS Institute, Cary, NC, USA) was applied for 
statistical analysis.
Results
Effects of acute imipramine treatment on the FST
The effects of acute imipramine treatment at various 
doses on the FST are shown in Figure 1. In this experi-
ment, imipramine was administered at ZT1. Williams test 
detected a significant reduction of immobility and a sig-
nificant increase of climbing at doses equal to or higher 
than 20 mg/kg of imipramine (immobility: p = 0.0210, 
0.0197, and 0.0275 for 20, 30, and 50 mg/kg, respectively; 
climbing: p = 0.0245, 0.0068, and 0.0078 for 20, 30, and 
50 mg/kg, respectively). Since the effect at 30 mg/kg was 
larger than the effect at other doses, we used imipramine 
at 30 mg/kg in the following analysis.
Figure 1: Imipramine exerts dose-dependent 
antidepressant actions in rats. The rats received 
imipramine intraperitoneally, after which they were 
subjected to the forced swim test. Each column represents 
the mean ± standard error of the mean (SEM) (n = 6 – 8). 
*p < 0.05, **p < 0.01 vs. control by Williams test.
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The rats treated with imipramine at ZT1 or ZT13 were 
subjected to the FST in order to analyze the effect of 
 dosing time on antidepressant activity. The results are 
shown in Figure 2. Imipramine significantly reduced 
immobility and increased climbing when administered at 
ZT1 (p = 0.0009 and p = 0.0126, respectively) (Figure 2A), 
but not at ZT13 (Figure 2B).
Plasma concentration of imipramine
The plasma concentrations of imipramine and its metab-
olite, desipramine, following imipramine treatment 
are shown in Figure 3. Two-way ANOVA detected no 
 interaction (F1,8 = 0.0013, p = 0.9719). The main effect in 
compound, imipramine and desipramine, was significant 
(F1,8 = 34.0154, p = 0.0004). Although the main effect in 
dosing time was not significant (F1,8 = 3.8042, p = 0.0869), 
both imipramine and desipramine were slightly increased 
at ZT1 compared to ZT13.
Effects of chronic imipramine treatment on the FST
The effects of chronic imipramine treatment on the 
FST are shown in Figure 4. In this experiment, imipra-
mine was administered at ZT1 or ZT13 for 2 weeks. We 
used two doses: the same dose as in the acute treatment 
(30 mg/kg), and the dose that was not effective in the 
acute  treatment (10 mg/kg). At low dose, the ZT1 group 
showed 24% reduction in immobility and 116% increase 
in climbing against the control (p = 0.0126 and p = 0.0144, 
respectively) (Figure 4A). The differences between ZT1 
and ZT13 were not significant (p = 0.1359 for immobil-
ity, p = 0.1778 for climbing). At high dose, significant 
differences in immobility and climbing were detected in 
the ZT1 and ZT13 groups against the control (p = 0.0001 
and p = 0.0030 for immobility, p < 0.0001 and p = 0.0006 
for climbing, respectively) (Figure 4B). The differences 
between ZT1 and ZT13 were not significant (p = 0.4310 
for immobility, p = 0.0883 for climbing).
Effects of chronic imipramine administration on 
adrenergic receptors
In order to investigate the alterations of the noradrener-
gic system induced by chronic treatment of imipramine, 
the protein levels of α1AR and α2AR were analyzed with 
western blotting (Figure 5). No significant differences 
were detected in the levels of α1AR and α2AR. However, 
the mean values of imipramine-treated groups were lower 
than those of the control. In particular, imipramine at ZT1 
resulted in 37% reduction of α2AR in the hippocampus 
against the control, although the difference was not sig-
nificant (p = 0.1018 vs. control, p = 0.6794 vs. ZT13).
Discussion
The present study examined the chronopharmacological 
effects of acute and chronic imipramine treatment. We 
showed that imipramine works more efficiently in the 
morning than in the evening in rats. The antidepressant 
effect was observed in the morning (ZT1), but not in the 
evening (ZT13) with a single dose of 30 mg/kg of imipra-
mine. The same trend was observed in the chronic treat-
Figure 2: Acute imipramine treatment produces dosing 
time-dependent effects in the forced swim test (FST). 
The rats were administered imipramine at ZT1 (A) or ZT13 
(B). One hour after imipramine administration, the rats 
were subjected to the FST. Each column represents the 
mean ± standard error of the mean (SEM) (n = 10 – 13). 
*p < 0.05, **p < 0.01 by Student’s t-test.
Figure 3: Dosing time affects the plasma levels of 
imipramine and desipramine following acute 
imipramine treatment. Imipramine (30 mg/kg) 
was administered at ZT1 or ZT13, and the plasma 
concentrations of imipramine and desipramine were 
measured 1 hour later. Each column represents the 
mean ± standard error of the mean (SEM) (n = 3). *p < 
0.05 by 2-way analysis of variance (ANOVA).
Figure 4: Chronic imipramine treatment produces 
dosing time-dependent effects in the forced swim 
test (FST). The rats were administered imipramine at 
ZT1 or ZT13 for 2 weeks, and then subjected to the 
FST. The effects of chronic imipramine treatment at 10 
mg/kg (A) and 30 mg/kg (B) are shown. Each column 
represents the mean ± standard error of the mean (SEM) 
(n = 8 – 18). *p < 0.05, **p < 0.01 by Tukey’s test.
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ment model. Chronic imipramine in the morning induced 
antidepressant effects in the FST even when the dose 
was lower than the effective dose in the acute treatment 
model. Chronic imipramine might increase the drug sus-
ceptibility of the rat brain most efficiently in the morning. 
To our knowledge, this is the first report that shows the 
chronopharmacological effects of an antidepressant in a 
chronic treatment model. Since antidepressants are usu-
ally used chronically in clinical settings, this model could 
be a useful model to analyze the chronopharmacological 
profile of antidepressants and the underlying mechanism 
of their chronopharmacological activity.
In the chronic treatment model, the rats were adminis-
tered a low dose (10 mg/kg) of imipramine one hour before 
the FST as described in the Methods. Since imipramine 
was ineffective at this dose when administered acutely 
(Figure 1), the reduction of immobility and the increase 
of climbing observed in Figure 4 could not be because of 
the acute effect of the last low dose administration. This 
suggests that the chronic imipramine treatment caused 
these antidepressant effects. Chronic imipramine treat-
ment might induce alterations of the adrenergic system 
(target system of imipramine) such as an enhancement 
of noradrenergic neurons’ susceptibility to imipramine, 
which would induce the antidepressant effects seen after 
the administration of a low dose of imipramine.
Chronopharmacological effects can be induced by the 
circadian fluctuation of the pharmacokinetics or pharma-
codynamics of a drug [2]. Various drugs show dosing time-
dependent pharmacokinetics [23, 33–35]. Imipramine is 
metabolized to desipramine by CYP1A2, 3A4, and 2C19, 
and imipramine and desipramine are hydroxylated to the 
2-OH form by CYP2D6 [36, 37]. Both imipramine and 
desipramine have antidepressant activity, while the 2-OH 
form of both compounds does not have antidepressant 
activity. Therefore, intra-day fluctuation of the activity of 
CYP2D6 could explain the chronopharmacological action 
of imipramine. The expression of CYPs is controlled by 
biological clocks, and their expression and activity show 
a circadian rhythm [38–43]. The expression of CYP2D9, 
the murine homolog of human CYP2D6, shows a circa-
dian rhythm with a peak at night in the mouse liver [43]. 
Figure 3 shows that the plasma concentrations of imipra-
mine and desipramine were 17–37% higher at ZT1 than at 
ZT13. Although the difference (p = 0.0869) did not meet 
the criteria of statistical significance, we suspect that the 
circadian fluctuation of CYP2D9 might have caused the 
difference in imipramine concentrations between ZT1 
and ZT13, which might contribute to the chronopharma-
cological action of imipramine to some extent.
Pharmacodynamics should also be considered. In brain 
monoaminergic systems, the contents of neurotransmit-
ters and the expression of receptors and transporters 
show circadian rhythm [20, 21, 44]. Since imipramine 
exerts antidepressant activity by its interaction with the 
serotonergic and noradrenergic systems, the  circadian 
rhythm of these neuronal systems could cause the 
 chronopharmacological action of imipramine.
In the modified FST, the increase of swimming and 
climbing is related to the activation of serotonergic and 
noradrenergic activity in the brain, respectively [26]. 
Imipramine increased climbing in the present study, sug-
gesting that the noradrenergic system should dominantly 
contribute to the antidepressant activity of imipramine in 
rats. We suspected that desipramine played a major role 
in this noradrenergic effect. Imipramine and desipramine 
inhibit both the serotonin transporter (SERT) and the 
noradrenaline transporter (NAT). However, the selectivity 
was different between imipramine and desipramine. The 
inhibitory action of imipramine is 27 times more potent 
on SERT than on NAT, whereas that of desipramine is 21 
times more potent on NAT than on SERT [45]. Since the 
plasma concentration of desipramine was higher than 
that of imipramine (Figure 3), the effects of desipramine 
might appear dominantly in the FST.
Most antidepressants are effective only after chronic 
treatment in clinical settings. Chronic treatment with 
antidepressants induces alterations in the brain function, 
which may lead to the alleviation of depressive symptoms. 
The involvement of α2AR has been reported both in ani-
mal and clinical studies. Brain α2AR density is upregulated 
in patients with depression [30, 46]. Chronic treatment 
with a tricyclic antidepressant induces the downregula-
tion of α2AR in various brain regions of model animals 
[30, 47]. The present results are consistent with those of 
previous studies. Although we could not detect significant 
differences, the protein levels of α1AR and α2AR tended 
to be reduced following chronic imipramine treatment 
(Figure 5). Comparing ZT1 and ZT3 groups, the reduc-
tion seemed larger in the ZT1 group, especially for α2AR 
in the  hippocampus. Since α2AR exists in the presynaptic 
Figure 5: Chronic imipramine treatment alters the 
protein level of adrenergic receptors. Imipramine 
(30 mg/kg) was chronically administered at ZT1 or 
ZT13, and the protein levels of α1AR and α2AR were 
analyzed with western blotting. The levels of α1AR (A, 
B) and α2AR (C, D) in the prefrontal cortex (PFC) (A, C) 
and hippocampus (B, D) are shown. Each column shows 
the mean ± standard error of the mean (SEM) (n = 4). No 
statistically significant difference was detected between 
groups by Tukey’s test.
Kawai et al: Time of Administration of Acute or Chronic Doses of Imipramine Affects its 
Antidepressant Action in Rats
Art. 5, page 6 of 9  
neurons and negatively modulates noradrenaline release 
[30], the downregulation of the α2AR might lead to 
increased noradrenergic neural transmission, which 
might induce antidepressant effects.
There are some concerns about the validity of the FST. 
In this study, a low dose (10 mg/kg) of imipramine was 
sufficient for an antidepressant effect in the chronic 
model; however, a higher dose was necessary to have an 
antidepressant effect in the acute model. These results are 
consistent with previous studies looking at other drugs. 
Amitriptyline, mianserin, desipramine, and fluoxetine 
have an antidepressant effect in the FST when chroni-
cally administered at a particular dose, but this same dose 
does not have an antidepressant effect when administered 
acutely [48, 49]. Another study indicated that some drugs, 
such as mepyramine and promethazine, are effective with 
acute treatment but not with chronic treatment [50]. 
These findings suggest that the mechanism involved in 
the imipramine-induced anti-immobility effect in the FST 
is different in the chronic and acute models. Since chronic 
treatment is usually necessary for effective antidepressant 
therapy in clinical settings [24], the physiological changes 
observed in the acute model may be different from the 
changes seen in human depression. The FST used in the 
acute model may not be a good model for the analysis of 
the mechanisms involved in human depression. However, 
the acute FST is a useful tool for high throughput screen-
ing and analysis of antidepressant activity.
There are some inconsistencies about the 
 chronopharmacological profile of antidepressant between 
the present results and those of previous studies. A tricy-
clic antidepressant, amitriptyline, shows circadian  activity 
rhythm with a peak at early night in an acute mouse 
model [20]. A serotonin noradrenaline reuptake inhibitor 
(SNRI), milnacipran, induces a large increase in climbing 
at ZT13 rather than at ZT1 in an acute rat model [21]. In 
the present study, imipramine induced a large reduction 
in immobility and an increase in climbing in the morning 
(ZT1) in an acute rat model (Figure 2). We are unable to 
explain these inconsistencies based on the available data. 
However, we suspect that differences in the mechanism of 
action might contribute to the different chronopharma-
cological profiles. Although amitriptyline, milnacipran, 
and imipramine inhibit both SERT and NAT, the relative 
activity to SERT and NAT is different among these com-
pounds [45]. Since serotonergic and noradrenergic sys-
tems show circadian activity rhythms with different peak 
times [21, 44], the relative activity of different antidepres-
sants on these neurons may be an important factor that 
determines their chronopharmacological profiles.
There are limitations to the present study. (1) The 
 chronopharmacological effect was analyzed with only 
two time points. (2) The contributions of neuronal sys-
tems other than the noradrenergic system were not 
addressed. (3) Antidepressant activity was evaluated only 
with the FST and by using normal naïve rats. Firstly, it is 
impossible to determine the exact time point at which 
imipramine shows maximal antidepressant activity dur-
ing the day. Although we observed higher antidepres-
sant activity in the morning than in the evening, the data 
could not exclude the possibility that imipramine shows 
maximal antidepressant activity during the afternoon or 
at midnight. Chronopharmacological analysis with three 
or more time points should be important to discuss 
the  precise chronopharmacological profiles of imipra-
mine and other antidepressants, as well as to clarify the 
 relationships between the chronopharmacological profile 
and the mechanism of action of antidepressants. Secondly, 
the present study analyzed the effect of chronic imipra-
mine administration only on the adrenergic  receptors. 
However, other neuronal systems such as the serotoner-
gic, dopaminergic, and glutamatergic systems may also 
play an important role in the action of antidepressants 
[51]. We could not exclude the possibility that these 
 systems show larger circadian fluctuations of the activity 
compared to the adrenergic system, and that these fluc-
tuations are crucial in the chronopharmacological action 
of imipramine. The effects of antidepressants on these 
 systems and their circadian system functionality should 
be considered. Thirdly, the chronopharmacological effects 
of antidepressants in depression patients or depressive-
like animals are still unknown. Some physiological func-
tions in depressive-like animals may be impaired and 
different from those in normal animals, which may alter 
the chronopharmacological effects of the antidepressants. 
Some drugs cannot induce antidepressant effects in ani-
mal models of depression even though they have antide-
pressant effects in normal animals [52, 53]. Patients with 
depression and animal models of depression sometimes 
show disturbances in circadian system functionality [6–8, 
54–56]. Chronopharmacological profiles of antidepres-
sant activity in depressive-like animals could be differ-
ent from those in normal animals. Analyses using animal 
models of depression may clarify the chronopharmaco-
logical effects of antidepressants on behavior and brain 
monoaminergic systems in the depression.
Conclusion
In this study, we revealed the chronopharmacological 
activity of imipramine in rats. In particular, we found that 
chronic imipramine treatment produced dosing time-
dependent antidepressant effects at a dose that was inef-
fective when given acutely. In the FST, imipramine showed 
greater antidepressant effects in the morning than in the 
evening. Imipramine could interact with noradrenergic 
neurons more effectively in the morning than in the even-
ing, and the chronic interaction with the neurons might 
induce the alterations of the receptor expression, which 
might explain the dosing time-dependent antidepressant 
effects of imipramine. This low-dose chronic model using 
the FST might be a useful model for the chronopharmaco-
logical analysis of antidepressants.
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